CAP

CAP
Name	CAP
Specialty	Pulmonology, Infectious disease
Symptoms	Fever, cough, dyspnea, chest pain
Complications	Respiratory failure, sepsis, empyema
Onset	Acute
Causes	Bacterial, viral, fungal pathogens
Diagnosis	Chest imaging, microbiology, clinical criteria
Treatment	Antimicrobial therapy, supportive care

CAP Community-acquired pneumonia is an acute infectious process of the pulmonary parenchyma acquired outside health-care facilities. It commonly presents with fever, productive cough, pleuritic chest pain and dyspnea and can range from mild outpatient illness to life-threatening respiratory failure requiring intensive care. Management integrates clinical assessment, radiographic confirmation, microbiological testing, and empiric antimicrobial therapy guided by severity scores and local resistance patterns.

Definition and Overview

Community-acquired pneumonia denotes infection of lung tissue contracted in the nonnosocomial setting by pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, and respiratory viruses including Influenza virus and Respiratory syncytial virus. Clinical presentation overlaps with exacerbations of chronic cardiopulmonary conditions such as Chronic obstructive pulmonary disease and may mimic noninfectious processes like pulmonary embolism following Deep vein thrombosis or exacerbations related to Congestive heart failure. Severity assessment tools such as the CURB-65 and Pneumonia Severity Index help stratify risk and site-of-care decisions.

History and Etymology

Descriptions of lobar consolidation predate modern microbiology, appearing in clinical texts contemporaneous with the rise of auscultation by René Laennec and pathological correlations advanced by Rudolf Virchow. The identification of key pathogens followed discoveries by Louis Pasteur and Robert Koch that established microbial causation. Antimicrobial therapy transformed outcomes after the introduction of Penicillin and subsequent classes such as Macrolide and Fluoroquinolone agents; emergence of resistance prompted stewardship movements exemplified by initiatives from the World Health Organization and national public health agencies.

Types and Classifications

Clinical and etiologic frameworks classify community-acquired pneumonia by radiographic pattern (lobar, multilobar, bronchopneumonia, interstitial), presumed pathogen (typical vs atypical), and host factors (young adult, elderly, immunocompromised). Radiographic lobar consolidation contrasts with interstitial infiltrates seen in infections by Mycoplasma pneumoniae and viral agents such as Adenovirus. Special categories include post-influenza bacterial superinfection often involving Staphylococcus aureus and necrotizing pneumonia associated with organisms like Pseudomonas aeruginosa in patients with structural lung disease including Bronchiectasis.

Causes and Pathophysiology

Pathogenesis involves inhalation or microaspiration of pathogenic organisms with evasion of mucociliary clearance and alveolar macrophage defenses mediated by factors such as IgA, surfactant, and complement pathways described in immunology texts like those by Paul Ehrlich and Ilya Metchnikoff. Bacterial virulence factors—polysaccharide capsule in Streptococcus pneumoniae, protein A in Staphylococcus aureus—promote adherence and immune evasion. Viral cytopathic effects from Influenza A virus predispose to secondary bacterial invasion. Host risk modifiers include age-related immunosenescence, chronic conditions like Diabetes mellitus, and smoking-related impairment linked to studies from institutions such as the Centers for Disease Control and Prevention.

Diagnosis and Evaluation

Diagnosis combines history, physical examination, laboratory testing, and imaging. Chest radiography showing new infiltrate plus compatible clinical features is central; computed tomography from centers like Mayo Clinic improves sensitivity. Microbiologic confirmation uses sputum culture, blood culture, urinary antigen assays for Legionella pneumophila and Streptococcus pneumoniae, and PCR panels detecting SARS-CoV-2 and other respiratory viruses. Severity scores—CURB-65 and Pneumonia Severity Index—guide hospitalization decisions, while biomarkers such as procalcitonin have been evaluated in trials published by groups at Johns Hopkins University and Imperial College London.

Treatment and Management

Empiric outpatient regimens often include a macrolide or doxycycline, while inpatient therapy usually employs a beta-lactam plus macrolide or a respiratory fluoroquinolone, consistent with guidelines from bodies like the Infectious Diseases Society of America and European Respiratory Society. Supportive care addresses oxygenation, fluid balance, and complications; severe cases may require mechanical ventilation in units modeled on protocols from Society of Critical Care Medicine. Antimicrobial stewardship programs and local antibiograms from institutions such as National Institutes of Health inform de-escalation. Vaccination against Streptococcus pneumoniae and Influenza virus reduces incidence and severity.

Epidemiology and Public Health Implications

Community-acquired pneumonia remains a leading cause of infectious morbidity and mortality worldwide, with burden estimates produced by agencies like the World Health Organization and the Centers for Disease Control and Prevention. Incidence varies by age, with peaks in young children and older adults; comorbidities such as Chronic obstructive pulmonary disease and HIV/AIDS increase risk. Antimicrobial resistance trends monitored by networks including the European Centre for Disease Prevention and Control affect empiric therapy choices. Public health strategies emphasize vaccination campaigns, smoking cessation initiatives supported by World Health Organization policy, and surveillance systems exemplified by Global Influenza Surveillance and Response System.

Category:Respiratory infections